|
Segment Reporting – Corporate and Other/Merck Group |
|
|
|
|
||||||||
|
|
|
|
|
|
|
|
|
| ||||
|
|
|
|
|
|
Corporate and Other | |||||||
|
EUR million |
Q2 |
Q2 |
Jan.–June |
Jan.–June | ||||||||
| ||||||||||||
|
Sales |
|
|
|
|
– |
– |
– |
– | ||||
|
Royalty and commission income* |
|
|
|
|
– |
– |
– |
– | ||||
|
Total revenues |
|
|
|
|
– |
– |
– |
– | ||||
|
Gross margin |
|
|
|
|
– |
– |
– |
– | ||||
|
Marketing and selling expenses* |
|
|
|
|
–0.3 |
0.1 |
–1.4 |
–0.4 | ||||
|
Royalty and commission expenses* |
|
|
|
|
– |
– |
– |
– | ||||
|
Administration expenses |
|
|
|
|
–17.9 |
–14.5 |
–34.2 |
–28.4 | ||||
|
Other operating expenses and income |
|
|
|
|
18.6 |
–6.3 |
–15.5 |
–14.1 | ||||
|
Research and development |
|
|
|
|
–0.1 |
0.3 |
– |
–0.1 | ||||
|
Operating result |
|
|
|
|
2.0 |
–20.3 |
–49.5 |
–42.9 | ||||
|
Exceptional items |
|
|
|
|
–1.2 |
– |
–1.2 |
– | ||||
|
Earnings before interest and tax (EBIT) |
|
|
|
|
0.8 |
–20.3 |
–50.7 |
–42.9 | ||||
|
Net operating assets** |
|
|
|
|
– |
– |
43.1 |
37.4 | ||||
|
Segment liabilities** |
|
|
|
|
– |
– |
–13.8 |
–15.7 | ||||
|
Capital spending on property, plant and equipment |
|
0.1 |
–0.1 |
0.3 |
–0.1 | |||||||
|
Investments in intangible assets |
|
|
|
|
2.4 |
2.9 |
3.3 |
5.4 | ||||
|
Depreciation |
|
|
|
|
–0.5 |
–0.4 |
–1.1 |
–1.4 | ||||
|
Impairment losses |
|
|
|
|
– |
– |
– |
– | ||||
|
Net cash flows from operating activities |
|
|
|
|
–70.1 |
–183.2 |
–181.9 |
–265.1 | ||||
|
Net cash flows from investing activities |
|
|
|
|
–8.8 |
–789.7 |
1,336.0 |
–1,040.4 | ||||
|
Free cash flow |
|
|
|
|
–76.2 |
–185.9 |
–196.7 |
–270.6 | ||||
|
Underlying free cash flow |
|
|
|
|
–72.7 |
–185.9 |
–181.3 |
–270.6 | ||||
|
FCR in % |
|
|
|
|
– |
– |
– |
– | ||||
|
ROS in % |
|
|
|
|
– |
– |
– |
– | ||||
|
|
|
|
|
|
|
|
|
| ||||
|
|
|
|
|
|
Merck Group | |||||||
|
EUR million |
|
|
|
|
Q2 |
Q2 |
Jan.–June |
Jan.–June | ||||
|
Sales |
|
|
|
|
2,102.8 |
1,826.4 |
4,125.6 |
3,583.3 | ||||
|
Royalty and commission income* |
|
|
|
|
105.2 |
83.4 |
181.3 |
184.9 | ||||
|
Total revenues |
|
|
|
|
2,208.0 |
1,909.7 |
4,306.9 |
3,768.2 | ||||
|
Gross margin |
|
|
|
|
1,690.8 |
1,392.0 |
3,303.0 |
2,793.7 | ||||
|
Marketing and selling expenses* |
|
|
|
|
–540.2 |
–466.7 |
–1,008.4 |
–920.6 | ||||
|
Royalty and commission expenses* |
|
|
|
|
–117.3 |
–101.2 |
–239.5 |
–198.6 | ||||
|
Administration expenses |
|
|
|
|
–115.2 |
–108.1 |
–219.6 |
–214.9 | ||||
|
Other operating expenses and income |
|
|
|
|
–109.4 |
–44.7 |
–244.4 |
–129.8 | ||||
|
Research and development |
|
|
|
|
–338.8 |
–340.6 |
–686.0 |
–653.5 | ||||
|
Operating result |
|
|
|
|
326.2 |
184.5 |
621.0 |
382.6 | ||||
|
Exceptional items |
|
|
|
|
–1.2 |
– |
–1.2 |
–68.8 | ||||
|
Earnings before interest and tax (EBIT) |
|
|
|
|
325.0 |
184.5 |
619.8 |
313.8 | ||||
|
Net operating assets** |
|
|
|
|
– |
– |
13,464.4 |
12,346.7 | ||||
|
Segment liabilities** |
|
|
|
|
– |
– |
–1,550.1 |
–1,401.0 | ||||
|
Capital spending on property, plant and equipment |
91.2 |
100.6 |
155.9 |
189.7 | ||||||||
|
Investments in intangible assets |
|
|
|
|
17.0 |
18.3 |
31.0 |
45.3 | ||||
|
Depreciation |
|
|
|
|
–227.4 |
–219.8 |
–447.6 |
–443.8 | ||||
|
Impairment losses |
|
|
|
|
–7.4 |
–0.2 |
–33.6 |
–0.2 | ||||
|
Net cash flows from operating activities |
|
|
|
|
466.2 |
192.3 |
744.9 |
475.0 | ||||
|
Net cash flows from investing activities |
|
|
|
|
–112.5 |
–900.2 |
1,157.0 |
–1,266.6 | ||||
|
Free cash flow |
|
|
|
|
356.4 |
79.2 |
551.2 |
243.2 | ||||
|
Underlying free cash flow |
|
|
|
|
359.9 |
79.2 |
566.5 |
243.2 | ||||
|
FCR in % |
|
|
|
|
16.3 |
4.1 |
13.2 |
6.5 | ||||
|
ROS in % |
|
|
|
|
14.8 |
9.7 |
14.4 |
10.2 | ||||